Abstract
PURPOSE: The purpose of this statement is to review the literature on childhood stroke and to provide recommendations for optimal diagnosis and treatment. This statement is intended for physicians who are responsible for diagnosing and treating infants, children, and adolescents with cerebrovascular disease. METHODS: The Writing Group members were appointed by the American Heart Association Stroke Councilĝ€™s Scientific Statement Oversight Committee. The panel included members with several different areas of expertise. Each of the panelĝ€™s recommendations was weighted by applying the American Heart Association Stroke Councilĝ€™s Levels of Evidence grading algorithm. After being reviewed by panel members, the manuscript was reviewed by 4 expert peer reviewers and by members of the Stroke Council Leadership Committee and was approved by the American Heart Association Science Advisory and Coordinating Committee. We anticipate that this statement will need to be updated in 4 years. RESULTS: Evidence-based recommendations are provided for the prevention of ischemic stroke caused by sickle cell disease, moyamoya disease, cervicocephalic arterial dissection, and cardiogenic embolism. Recommendations on the evaluation and management of hemorrhagic stroke also are provided. Protocols for dosing of heparin and warfarin in children are suggested. Also included are recommendations on the evaluation and management of perinatal stroke and cerebral sinovenous thrombosis in children.
Original language | English |
---|---|
Pages (from-to) | 2644-2691 |
Number of pages | 48 |
Journal | Stroke |
Volume | 39 |
Issue number | 9 |
DOIs | |
State | Published - Sep 1 2008 |
Externally published | Yes |
Fingerprint
Keywords
- AHA Scientific Statements
- Children
- Stroke
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Clinical Neurology
- Advanced and Specialized Nursing
- Medicine(all)
Cite this
Management of stroke in infants and children : A scientific statement from a special writing group of the american heart association stroke council and the council on cardiovascular disease in the young. / Roach, E. Steve; Golomb, Meredith; Adams, Robert; Biller, Jose; Daniels, Stephen; Deveber, Gabrielle; Ferriero, Donna; Jones, Blaise V.; Kirkham, Fenella J.; Scott, R. Michael; Smith, Edward R.
In: Stroke, Vol. 39, No. 9, 01.09.2008, p. 2644-2691.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Management of stroke in infants and children
T2 - A scientific statement from a special writing group of the american heart association stroke council and the council on cardiovascular disease in the young
AU - Roach, E. Steve
AU - Golomb, Meredith
AU - Adams, Robert
AU - Biller, Jose
AU - Daniels, Stephen
AU - Deveber, Gabrielle
AU - Ferriero, Donna
AU - Jones, Blaise V.
AU - Kirkham, Fenella J.
AU - Scott, R. Michael
AU - Smith, Edward R.
PY - 2008/9/1
Y1 - 2008/9/1
N2 - PURPOSE: The purpose of this statement is to review the literature on childhood stroke and to provide recommendations for optimal diagnosis and treatment. This statement is intended for physicians who are responsible for diagnosing and treating infants, children, and adolescents with cerebrovascular disease. METHODS: The Writing Group members were appointed by the American Heart Association Stroke Councilĝ€™s Scientific Statement Oversight Committee. The panel included members with several different areas of expertise. Each of the panelĝ€™s recommendations was weighted by applying the American Heart Association Stroke Councilĝ€™s Levels of Evidence grading algorithm. After being reviewed by panel members, the manuscript was reviewed by 4 expert peer reviewers and by members of the Stroke Council Leadership Committee and was approved by the American Heart Association Science Advisory and Coordinating Committee. We anticipate that this statement will need to be updated in 4 years. RESULTS: Evidence-based recommendations are provided for the prevention of ischemic stroke caused by sickle cell disease, moyamoya disease, cervicocephalic arterial dissection, and cardiogenic embolism. Recommendations on the evaluation and management of hemorrhagic stroke also are provided. Protocols for dosing of heparin and warfarin in children are suggested. Also included are recommendations on the evaluation and management of perinatal stroke and cerebral sinovenous thrombosis in children.
AB - PURPOSE: The purpose of this statement is to review the literature on childhood stroke and to provide recommendations for optimal diagnosis and treatment. This statement is intended for physicians who are responsible for diagnosing and treating infants, children, and adolescents with cerebrovascular disease. METHODS: The Writing Group members were appointed by the American Heart Association Stroke Councilĝ€™s Scientific Statement Oversight Committee. The panel included members with several different areas of expertise. Each of the panelĝ€™s recommendations was weighted by applying the American Heart Association Stroke Councilĝ€™s Levels of Evidence grading algorithm. After being reviewed by panel members, the manuscript was reviewed by 4 expert peer reviewers and by members of the Stroke Council Leadership Committee and was approved by the American Heart Association Science Advisory and Coordinating Committee. We anticipate that this statement will need to be updated in 4 years. RESULTS: Evidence-based recommendations are provided for the prevention of ischemic stroke caused by sickle cell disease, moyamoya disease, cervicocephalic arterial dissection, and cardiogenic embolism. Recommendations on the evaluation and management of hemorrhagic stroke also are provided. Protocols for dosing of heparin and warfarin in children are suggested. Also included are recommendations on the evaluation and management of perinatal stroke and cerebral sinovenous thrombosis in children.
KW - AHA Scientific Statements
KW - Children
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=52449090507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52449090507&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.108.189696
DO - 10.1161/STROKEAHA.108.189696
M3 - Article
C2 - 18635845
AN - SCOPUS:52449090507
VL - 39
SP - 2644
EP - 2691
JO - Stroke
JF - Stroke
SN - 0039-2499
IS - 9
ER -